Adaptyx Biosciences, a biowearables company developing the first platform for continuous, multi-analyte molecular monitoring, today announced it has raised $14 million in seed financing, bringing total funding to $23 million since inception. The round was led by Interlagos, with significant participation from Overwater Ventures, and joined by Starbloom Capital, Stanford University, the Chan Zuckerberg Biohub, Hyperlink Ventures, Cantos Ventures, Humba Ventures, and Seaside Ventures.

Adaptyx's biowearable platform redefines continuous health monitoring, moving beyond glucose to capture a much wider range of human biochemistry - including small molecules, electrolytes, hormones, drugs, and proteins - making visible what has long been hidden between lab visits. By pairing continuous molecular sensing with AI-powered analytics, the platform transforms these data streams into actionable insights, enabling earlier detection of health trends and timely interventions before issues escalate.